Holen Sie sich die Stockscreener-App
1.96
0.00%
0.00
Handel nachbörslich:
2.09
0.13
+6.63%
Gri Bio Inc Aktie (GRI) Neueste Nachrichten
Form DEF 14A Matinas BioPharma Holdings Inc For: 29 September By Investing.com - Investing.com Nigeria
GRI Bio Announces Virtual 2026 Annual Stockholder Meeting and Proxy Proposals - kalkinemedia.com
GRI Bio, Inc. SEC Filing (Sep 28, 2026) - Stock Titan
GRI Bio executives to present at IPF Summit this week - Investing.com
GRI Bio executives to present at IPF Summit this week By Investing.com - Investing.com Nigeria
Gri Bio, Inc. Highlights Immune Modulation and Phase 2A Development Insights in IPF At the 10Th IPF Summit - marketscreener.com
GRI Bio Company Profile & Introduction - Moomoo
GRI Bio, Inc.Common Stock (NQ: GRI - The Chronicle-Journal
What date does GRI Bio, Inc.'s (GRI) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
GRI Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a IPF Biomarker Data - TipRanks
Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621 - Investing.com Nigeria
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - Stock Titan
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
What Put GRI Bio (NASDAQ:GRI) on the Nasdaq Composite Radar? - kalkinemedia.com
GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade
GRI Bio Jumps As Positive IPF Drug Data Nears ERS Stage - timothysykes.com
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF - HCPLive
GRI Bio Surges As Phase 2a IPF Data Near ERS Reveal - timothysykes.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GRI|GRI Bio Inc|Price:2.880|Chg%:+0.590 - TradingKey
GRI Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.71% Share GainEarnings Expansion Phase - dars.gov.et
GRI Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.91 Per Share Beats EstimatesLow Estimate Range - dars.gov.et
GRI Bio will present data on its once-daily oral drug in Barcelona this September - Stock Titan
OSRH Stock Price and Chart — OTC:OSRH - tradingview.com
Fortis (FTS) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.77% Higher in the Latest ReadingConsensus Beat Rate - vinanet.vn
CHGA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital - Moomoo
GRI (GRI) EPS and Revenue: Reported EPS Misses Expectations in the Latest Reading; Market Move: The Stock Loses 3.47% in the Current UpdateEarnings Forecast Report - vinanet.vn
GRI Bio Inc. (GRI) Climbs 3.6% to $1.73 as Buyers Defend Key SupportWyckoff Accumulation - vinanet.vn
GRI Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss of $1.61 Per Share, Yet Stock Closes Up 3.59 - vinanet.vn
GRI Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Shares Slide 5.65%Earnings Forecast Report - vinanet.vn
GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView
Form 10-Q GRI Bio, Inc. For: Jun 30 - StreetInsider
GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.ca
GRI Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage BurnGuidance Accuracy Score - dars.gov.et
GRI Bio Inc (GRI) Cash Flow - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):